Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | SCG101 |
Trade Name | |
Synonyms | SCG-101|SCG 101 |
Drug Descriptions |
SCG101 comprises CD4- and CD8-positive autologous T-lymphocytes engineered to express a T-cell receptor targeting HBsAg, which potentially induce cytotoxicity against tumor cells and enhance antitumor immune activity (Journal for ImmunoTherapy of Cancer 2022;10). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C187331 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
SCG101 | SCG101 | 0 | 1 |